Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
2 hedge funds and large institutions have $3.56M invested in Seelos Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
27% less capital invested
Capital invested by funds: $4.9M → $3.56M (-$1.34M)
90% less call options, than puts
Call options by funds: $7K | Put options by funds: $68K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$1.66M |
| 2 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$80K |
| 3 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$43.8K |
| 4 |
RC
Randolph Company
Cincinnati,
Ohio
|
-$16K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $6K | – | – | – |
|
27
Citigroup
New York
| $3K | – | – | – |
|
28
Morgan Stanley
New York
| $2K | – | – | – |
|
|
RC
29
RegentAtlantic Capital
Morristown,
New Jersey
| $1.33K | – | – | – |
|
|
HDIM
30
Hanson & Doremus Investment Management
Burlington,
Vermont
| $1K | – | – | – |
|
31
Simplex Trading
Chicago,
Illinois
| $1K | – | – | – |
|
|
ST
32
Sphinx Trading
Chicago,
Illinois
| $1K | – | – | – |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $4 | – | – | – |
|
|
VAM
34
Visium Asset Management
New York
| – | -$1.66M | -1 | Closed |
|
|
HCM
35
Highlander Capital Management
Short Hills,
New Jersey
| – | -$43.8K | – | – |
|
|
RC
36
Randolph Company
Cincinnati,
Ohio
| – | -$16K | – | – |
|
|
RCM
37
Rotella Capital Management
Bellevue,
Washington
| – | -$80K | – | – |
|
|
SM
38
Sabby Management
Miami Beach,
Florida
| – | -$26 | – | – |
|
|
TRCT
39
Tower Research Capital (TRC)
New York
| – | -$12K | – | – |
|
SEEL Hedge Fund Activity: Q4 2014 in Review
2 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2014, worth a combined $3.56M — down 27% from $4.9M a quarter earlier.
Fund positioning in SEEL was balanced in Q4 2014: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $1.52M. The largest seller was Visium Asset Management, exiting entirely with an estimated $1.66M sold.
- 2 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $3.56M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2014, down 27% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2014 and 1 closed out, a net change of 0 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2014 was Sarissa Capital Management, an estimated $1.52M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2014 was Visium Asset Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2014.